Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ACE-232 |
| Synonyms | |
| Therapy Description |
ACE-232 is a non-steroidal inhibitor of CYP11A1, which potentially reduces testosterone biosynthesis and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 6881). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ACE-232 | ACE 232|ACE232 | ACE-232 is a non-steroidal inhibitor of CYP11A1, which potentially reduces testosterone biosynthesis and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 6881). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06801236 | Phase I | ACE-232 | Phase 1 Study of ACE-232 to Treat Patients with Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |